Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Ambispective, Non-interventional, Multiple Cohort Study to Assess the Management of Osimertinib Treatment in Patients With EGFRm Non-small Cell Lung Cancer Under Real-world Conditions in Spain

NCT06068049 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06068049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06068049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Ambispective, Non-interventional, Multiple Cohort Study to Assess the Management of Osimertinib Treatment in Patients With EGFRm Non-small Cell Lung Cancer Under Real-world Conditions in Spain
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
July 28, 2023
Completion date
June 15, 2029
Enrollment
500 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer